Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines

Journal of Proteomics

Volumn 75, Issue 12, 2012, Pages 3747-3759

  Alhamdani, Mohamed Saiel Saeed ^a   Youns, Mahmoud ^b   Buchholz, Malte ^c   Gress, Thomas M ^c   Beckers, Marie Claire ^d   Maréchal, Daniel ^d   Bauer, Andrea ^a   Schröder, Christoph ^a   Hoheisel, Jörg D ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Ein Helwan   (Egypt)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d EUROGENTEC S A   (Belgium)

Author keywords

Antibody microarray; Oncoproteomics; Pancreatic cancer; Pancreatic cancer cell lines; Pancreatic ductal adenocarcinoma

Indexed keywords

PROTEOME;

AMINO ACID SEQUENCE; ANTIBODY MICROARRAY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN CELL; IMMUNOASSAY; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOASSAY; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOME; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84862233043     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.042     Document Type: Article

References (85)

1. Warshaw A.L., Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992, 326:455-465.
2. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999, 117:1463-1484.
3. Rosty C., Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002, 16:37-52.
4. Misek D.E., Patwa T.H., Lubman D.M., Simeone D.M. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 2007, 5:1034-1041.
5. Yokoyama Y., Nimura Y., Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today 2009, 39:466-475.
6. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
7. Cecconi D., Palmieri M., Donadelli M. Proteomics in pancreatic cancer research. Proteomics 2011, 11:816-828.
8. Ulrich A.B., Schmied B.M., Standop J., Schneider M.B., Pour P.M. Pancreatic cell lines: a review. Pancreas 2002, 24:111-120.
9. Chen R., Pan S., Brentnall T.A., Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005, 4:523-533.
10. Pawa N., Wright J.M., Arulampalam T.H. Mass spectrometry based proteomic profiling for pancreatic cancer. JOP 2010, 11:423-426.
11. Vimalachandran D., Costello E. Proteomic technologies and their application to pancreatic cancer. Expert Rev Proteomics 2004, 1:493-501.
12. Alhamdani M.S., Hoheisel J.D. Antibody microarrays in proteome profiling. Molecular analysis and genome discovery 2011, 219-243. Wiley. second ed. R. Rapley, S. Harbron (Eds.).
13. Alhamdani M.S., Schröder C., Hoheisel J.D. Oncoproteomic profiling with antibody microarrays. Genome Med 2009, 1:68.
14. Hodgkinson V.C., ElFadl D., Drew P.J., Lind M.J., Cawkwell L. Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. J Proteomics 2011, 74:698-703.
15. Schröder C., Jacob A., Tonack S., Radon T.P., Sill M., Zucknick M., et al. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol Cell Proteomics 2010, [DOI: M900419-MCP200 [pii] http://dx.doi.org/10.1074/mcp.M-MCP200].
16. Li C., Simeone D.M., Brenner D.E., Anderson M.A., Shedden K.A., Ruffin M.T., et al. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res 2009, 8:483-492.
17. Ingvarsson J., Wingren C., Carlsson A., Ellmark P., Wahren B., Engstrom G., et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008, 8:2211-2219.
18. Chen S., LaRoche T., Hamelinck D., Bergsma D., Brenner D., Simeone D., et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007, 4:437-444.
19. Orchekowski R., Hamelinck D., Li L., Gliwa E., van Brocklin M., Marrero J.A., et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 2005, 65:11193-11202.
20. Hamelinck D., Zhou H., Li L., Verweij C., Dillon D., Feng Z., et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics 2005, 4:773-784.
21. Bauer A., Kleeff J., Bier M., Wirtz M., Kayed H., Esposito I., et al. Identification of malignancy factors by analyzing cystic tumors of the pancreas. Pancreatology 2009, 9:34-44.
22. Buchholz M., Kestler H.A., Bauer A., Bock W., Rau B., Leder G., et al. Specialized DNA arrays for the differentiation of pancreatic tumors. Clin Cancer Res 2005, 11:8048-8054.
23. Notterman D.A., Alon U., Sierk A.J., Levine A.J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001, 61:3124-3130.
24. Liu N., Furukawa T., Kobari M., Tsao M.S. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 1998, 153:263-269.
25. Alhamdani M.S., Schröder C., Werner J., Giese N., Bauer A., Hoheisel J. Single-step procedure for the isolation of proteins at near-native conditions from mammalian tissue for proteomic analysis on antibody microarrays. J Proteome Res 2010, 963-971.
26. Alhamdani M.S., Schroder C., Hoheisel J.D. Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays. Proteomics 2010, 10:3203-3207.
27. Ritchie M.E., Silver J., Oshlack A., Holmes M., Diyagama D., Holloway A., et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007, 23:2700-2707.
28. Taguchi Y.H., Oono Y. Relational patterns of gene expression via non-metric multidimensional scaling analysis. Bioinformatics 2005, 21:730-740.
29. Fellenberg K., Hauser N.C., Brors B., Neutzner A., Hoheisel J.D., Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci U S A 2001, 98:10781-10786.
30. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. [Article3].
31. Bhatia V.N., Perlman D.H., Costello C.E., McComb M.E. Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem 2009, 81:9819-9823.
32. Roda O., Chiva C., Espuna G., Gabius H.J., Real F.X., Navarro P., et al. A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells. Proteomics 2006, 6(Suppl. 1):S36-S41.
33. Bocci G., Danesi R., Marangoni G., Fioravanti A., Boggi U., Esposito I., et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 2004, 498:9-18.
34. Ouyang H., Mou L., Luk C., Liu N., Karaskova J., Squire J., et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000, 157:1623-1631.
35. Evers B.M., Townsend C.M., Upp J.R., Allen E., Hurlbut S.C., Kim S.W., et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991, 101:303-311.
36. Eisold S., Ryschich E., Linnebacher M., Giese T., Nauheimer D., Wild A., et al. Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer 2004, 100:1978-1986.
37. Frazier M.L., Pathak S., Wang Z.W., Cleary K., Singletary S.E., Olive M., et al. Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3. Pancreas 1990, 5:8-16.
38. Shi W., Meng Z., Chen Z., Luo J., Liu L. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem 2011, 347:117-125.
39. Wu Y.M., Nowack D.D., Omenn G.S., Haab B.B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009, 8:1876-1886.
40. Hardikar A.A., Marcus-Samuels B., Geras-Raaka E., Raaka B.M., Gershengorn M.C. Human pancreatic precursor cells secrete FGF2 to stimulate clustering into hormone-expressing islet-like cell aggregates. Proc Natl Acad Sci U S A 2003, 100:7117-7122.
41. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999, 59:4356-4362.
42. Pyrko P., Soriano N., Kardosh A., Liu Y.T., Uddin J., Petasis N.A., et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006, 5:19.
43. Heremans Y., Van De Casteele M., in't Veld P., Gradwohl G., Serup P., Madsen O., et al. Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3. J Cell Biol 2002, 159:303-312.
44. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59:987-990.
45. Mroczko B., Groblewska M., Gryko M., Kedra B., Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010, 24:256-261.
46. Duxbury M.S., Whang E.E. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun 2007, 354:190-196.
47. Ohhashi S., Ohuchida K., Mizumoto K., Fujita H., Egami T., Yu J., et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008, 28:2205-2212.
48. Fujita H., Ohuchida K., Mizumoto K., Itaba S., Ito T., Nakata K., et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 2010, 12:807-817.
49. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004, 10:2307-2318.
50. Zhao S., Ammanamanchi S., Brattain M., Cao L., Thangasamy A., Wang J., et al. Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem 2008, 283:11293-11301.
51. Jungert K., Buck A., von Wichert G., Adler G., Konig A., Buchholz M., et al. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007, 67:1563-1570.
52. Wada M., Yazumi S., Takaishi S., Hasegawa K., Sawada M., Tanaka H., et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 2004, 23:2401-2407.
53. Chen W.B., Lenschow W., Tiede K., Fischer J.W., Kalthoff H., Ungefroren H. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem 2002, 277:36118-36128.
54. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000, 14:927-939.
55. Murphy C.G., Moynahan M.E. BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J 2010, 16:39-47.
56. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271.
57. Lal G., Liu G., Schmocker B., Kaurah P., Ozcelik H., Narod S.A., et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000, 60:409-416.
58. Yachida S., Iacobuzio-Donahue C.A. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 2009, 133:413-422.
59. Pawlik T.M., Choti M.A. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007, 11:1057-1077.
60. Verslype C., Van Cutsem E., Dicato M., Cascinu S., Cunningham D., Diaz-Rubio E., et al. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007, 18(Suppl. 7):vii1-vii10.
61. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105:3041-3046.
62. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
63. Ricciardi S., Mey V., Nannizzi S., Pasqualetti G., Crea F., Del Tacca M., et al. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy 2010, 56:303-312.
64. El-Khoueiry A.B., Ramanathan R.K., Yang D.Y., Zhang W., Shibata S., Wright J.J., et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs 2011, 10.1007/s10637-011-9658-9.
65. Kindler H.L., Wroblewski K., Wallace J.A., Hall M.J., Locker G., Nattam S., et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2011, 10.1007/s10637-010-9526-z.
66. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006, 6:350-354.
67. Mlejnek P., Dolezel P., Kosztyu P. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N(6) -(3-iodobenzyl)-adenosine-5'-N-methyluronamide in human leukemia cells. J Cell Physiol 2011, 10.1002/jcp.22775.
68. Leitner I., Nemeth J., Feurstein T., Abrahim A., Matzneller P., Lagler H., et al. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother 2011, 66:834-839.
69. Robey R.W., Massey P.R., Amiri-Kordestani L., Bates S.E. ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 2010, 10:625-633.
70. Schlingensiepen K.H., Fischer-Blass B., Schmaus S., Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008, 177:137-150.
71. Hau P., Jachimczak P., Schlingensiepen R., Schulmeyer F., Jauch T., Steinbrecher A., et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007, 17:201-212.
72. Bramhall S.R., Neoptolemos J.P., Stamp G.W., Lemoine N.R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997, 182:347-355.
73. Kilian M., Gregor J.I., Heukamp I., Hanel M., Ahlgrimm M., Schimke I., et al. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 2006, 75:429-434.
74. Kloppel G., Hruban R.H., Longnecker D.S. Ductal adenocarcinoma of the pancreas. WHO classification of tumors: pathology and genetics of tumors of the digestive system 2000, 221-230. IARC Press, Lyon. A.D. Hamilton, L.A. Aaltonen (Eds.).
75. Adsay N.V., Basturk O., Cheng J.D., Andea A.A. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 2005, 15:254-264.
76. Andrianifahanana M., Moniaux N., Schmied B.M., Ringel J., Friess H., Hollingsworth M.A., et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001, 7:4033-4040.
77. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729.
78. Terada T., Ohta T., Sasaki M., Nakanuma Y., Kim Y.S. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol 1996, 180:160-165.
79. Porowska H., Paszkiewicz-Gadek A., Wosek J., Wnuczko K., Rusak M., Szczepanski M. Expression of MUC1 mucin in human umbilical vein endothelial cells (HUVEC). Folia Histochem Cytobiol 2010, 48:417-424.
80. Casey G., Yamanaka Y., Friess H., Kobrin M.S., Lopez M.E., Buchler M., et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993, 69:151-160.
81. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999, 5:119-127.
82. Safran H., Steinhoff M., Mangray S., Rathore R., King T.C., Chai L., et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001, 24:496-499.
83. Giehl K., Skripczynski B., Mansard A., Menke A., Gierschik P. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000, 19:2930-2942.
84. Al-Aynati M.M., Radulovich N., Ho J., Tsao M.S. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res 2004, 10:6598-6605.
85. Tascilar M., Skinner H.G., Rosty C., Sohn T., Wilentz R.E., Offerhaus G.J., et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001, 7:4115-4121.